What is the recommended assessment schedule for lurbinectedin's lasting effects?

What happens to lurbinectedin's effectiveness after several cycles of treatment?

Lurbinectedin's efficacy can drop after repeated cycles. Clinical data show objective response rates fall from 35% in patients receiving it as second-line therapy to 35% in third-line settings, but overall survival remains around 9.3 months across lines. Efficacy may also depend on performance status and tumor type.

What signs indicate that lurbinectedin's lasting effects have faded?

Signs that the drug's lasting effects have faded include disease progression on imaging or rise in tumor markers. Progression is usually measured by RECIST 1.1 criteria. Progression occurs earlier in patients who has lower performance status or who receive lurbinectedin's as third-line treatment.

What side effects persist long-term after stopping lurbinectedin's treatment?

Lurbinectedin's long-term side effects are rare. Patients often report fatigue, nausea, and myelosuppression that are acute rather than long-term. Bone marrow suppression is primarly acute and fades after the cycles finish. No specific long-term toxicity profile is reported in available data.

How does this drug affect patients who are older than 65?

Patients over 65 receive the same 3.2 mg/m² dose every 21 days as younger patients. Data from a pooled analysis of clinical trials show no difference in exposure or efficacy between age groups. No dose adjustment is needed for elderly patients.

How long does lurbinectedin's lasting effect remain after the treatment ends?

Data show that duration of response lasts around 5.3 months in patients receiving lurbinectedin's as second-line therapy. Duration of response is shorter in third-line settings. Duration of response is measured from the time of response to time of progression.